Cost-effectiveness thresholds: Pros and cons;Seuils de rentabilité: Avantages et inconvénients;Umbrales de rentabilidad: Ventajas e inconvenientes

Bulletin of the World Health Organization

Volumn 94, Issue 12, 2016, Pages 925-930

  Bertram, Melanie Y ^a   Lauer, Jeremy A ^a   De Joncheere, Kees ^a   Edejer, Tessa ^a   Hutubessy, Raymond ^a   Kieny, Marie Paule ^a   Hill, Suzanne R ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIVIL SOCIETY; COST-BENEFIT ANALYSIS; DECISION MAKING; FEASIBILITY STUDY; GROSS DOMESTIC PRODUCT; HEALTH CARE; MACROECONOMICS; PROFITABILITY; STAKEHOLDER; THRESHOLD; UNCERTAINTY ANALYSIS; WORLD HEALTH ORGANIZATION;

BUDGET; COST EFFECTIVENESS ANALYSIS; FEASIBILITY STUDY; GROSS NATIONAL PRODUCT; HUMAN; LAW; MONEY; ORGANIZATION; UNCERTAINTY; COST BENEFIT ANALYSIS; DECISION MAKING; GLOBAL HEALTH; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; WORLD HEALTH ORGANIZATION;

BUDGETS; COST-BENEFIT ANALYSIS; DECISION MAKING; GLOBAL HEALTH; GROSS DOMESTIC PRODUCT; HUMANS; WORLD HEALTH ORGANIZATION;

EID: 85006055085     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.15.164418     Document Type: Article

References (35)

1. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015 Feb 1;93(2):118-24. doi: http://dx.doi.org/10.2471/BLT.14.138206 PMID: 25883405
2. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001. Available from: http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf [cited 2016 Aug 18].
3. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997 Feb;16(1):1-31. doi: http://dx.doi.org/10.1016/S0167-6296(96)00506-1 PMID: 10167341
4. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low-and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics. 2009;27(11):903-17. doi: http://dx.doi.org/10.2165/10899580-000000000-00000 PMID: 19888791
5. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013 Dec 7;382(9908):1898-955. doi: http://dx.doi.org/10.1016/S0140-6736(13)62105-4 PMID: 24309475
6. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003 Dec 19;1(1):8. doi: http://dx.doi.org/10.1186/1478-7547-1-8 PMID: 14687420
7. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf [cited 2016 Aug 18].
8. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003 Dec 19;1(1):8. doi: http://dx.doi.org/10.1186/1478-7547-1-8 PMID: 14687420
9. Ranking vaccines: a prioritization framework. Phase I: demonstration of concept and a software blueprint. Washington: National Academies of Sciences, Engineering, and Medicine; 2012. Available from: http://www.nationalacademies.org/hmd/Reports/2012/Ranking-Vaccines-A-Prioritization-Framework-Phase-I.aspx [cited 2016 Mar 15].
10. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000 Apr 26;283(16):2116-21. doi: http://dx.doi.org/10.1001/jama.283.16.2116 PMID: 10791503
11. Yong JH, Beca J, Hoch JS. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada. Pharmacoeconomics. 2013 Mar;31(3):229-36. doi: http://dx.doi.org/10.1007/s40273-012-0022-5 PMID: 23322588
12. Hoomans T, Severens JL, van der Roer N, Delwel GO. Methodological quality of economic evaluations of new pharmaceuticals in the Netherlands. Pharmacoeconomics. 2012 Mar;30(3):219-27. doi: http://dx.doi.org/10.2165/11539850-000000000-00000 PMID: 22074610
13. Oostvogels AJ, De Wit GA, Jahn B, Cassini A, Colzani E, De Waure C, et al. Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review. Epidemiol Infect. 2015 Jul;143(9):1791-802. doi: http://dx.doi.org/10.1017/S0950268814001940 PMID: 25499823
14. Simoens S. Assessment of methodological quality of economic evaluations in belgian drug reimbursement applications. PLoS One. 2013 Dec 30;8(12):e85411. doi: http://dx.doi.org/10.1371/journal.pone.0085411 PMID: 24386474
15. Williams I, Bryan S. Lonely at the top and stuck in the middle? The ongoing challenge of using cost-effectiveness information in priority setting. Comment on “Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden”. Int J Health Policy Manag. 2015 Feb 15;4(3):185-7. doi: http://dx.doi.org/10.15171/ijhpm.2015.32 PMID: 25774376
16. Zelle SG, Vidaurre T, Abugattas JE, Manrique JE, Sarria G, Jeronimo J, et al. Cost-effectiveness analysis of breast cancer control interventions in Peru. PLoS One. 2013 Dec 10;8(12):e82575. doi: http://dx.doi.org/10.1371/journal.pone.0082575 PMID: 24349314
17. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015 Mar 17;162(6):397-406. doi: http://dx.doi.org/10.7326/M14-1336 PMID: 25775312
18. Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, et al.; WEF Study Group. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2014 May;59(5):1692-705. doi: http://dx.doi.org/10.1002/hep.27010 PMID: 24691835
19. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015 May 5;162(9):619-29. doi: http://dx.doi.org/10.7326/M14-1313 PMID: 25820703
20. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012;7(5):e36966. doi: http://dx.doi.org/10.1371/journal.pone.0036966 PMID: 22693561
21. Creswell J, Codlin AJ, Andre E, Micek MA, Bedru A, Carter EJ, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis. 2014 Jan 2;14(1):2. doi: http://dx.doi.org/10.1186/1471-2334-14-2 PMID: 24383553
22. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011 Apr;64(4):383-94. doi: http://dx.doi.org/10.1016/j.jclinepi.2010.04.026 PMID: 21195583
23. Schünemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, et al.; GRADE Working Group. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016 Feb 27;S0895-4356(16)00136-0. PMID: 26931285
24. Norheim OF, Baltussen R, Johri M, Chisholm D, Nord E, Brock D, et al. Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis. Cost Eff Resour Alloc. 2014 Aug 29;12(1):18. doi: http://dx.doi.org/10.1186/1478-7547-12-18 PMID: 25246855
25. Angelis A, Kanavos P. Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment. Pharmacoeconomics. 2016 May;34(5):435-46. doi: http://dx.doi.org/10.1007/s40273-015-0370-z PMID: 26739955
26. Ottersen T, Førde R, Kakad M, Kjellevold A, Melberg HO, Moen A, et al. A new proposal for priority setting in Norway: open and fair. Health Policy. 2016 Mar;120(3):246-51. doi: http://dx.doi.org/10.1016/j.healthpol.2016.01.012 PMID: 26851991
27. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making. Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001;19(11):1103-9. doi: http://dx.doi.org/10.2165/00019053-200119110-00004 PMID: 11735677
28. Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making. 2008 Sep-Oct;28(5):713-22. doi: http://dx.doi.org/10.1177/0272989X08315247 PMID: 18378939
29. Jakubiak-Lasocka J, Jakubczyk M. Cost-effectiveness versus cost-utility analyses: what are the motives behind using each and how do their results differ?—A Polish example. Value Health Reg Issues. 2014;4C:66-74. doi: http://dx.doi.org/10.1016/j.vhri.2014.06.008
30. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016 05 31;13(5):e1002032. doi: http://dx.doi.org/10.1371/journal.pmed.1002032 PMID: 27243629
31. Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res. 2013;5:29-36. doi: http://dx.doi.org/10.2147/CEOR.S38062 PMID: 23345984
32. Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):397-404. doi: http://dx.doi.org/10.1016/j.zefq.2014.06.017 PMID: 25444298
33. Youngkong S, Baltussen R, Tantivess S, Mohara A, Teerawattananon Y. Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand. Value Health. 2012 Sep-Oct;15(6):961-70. doi: http://dx.doi.org/10.1016/j.jval.2012.06.006 PMID: 22999148
34. Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? Health Econ. 2015 Jan;24(1):1-7. doi: http://dx.doi.org/10.1002/hec.3130 PMID: 25488707
35. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015 Feb;19(14):i-xxxiv, 1-503. doi: http://dx.doi.org/10.3310/hta19140 PMID: 25692211